argenx is a global immunology company developing medicines for people suffering from severe autoimmune disease. By translating scientific discoveries into potential innovative medicines, argenx is working to build a world-class portfolio of antibody-based agents currently ranging from early to late stages of clinical development.
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Our Immunology disease research combines our proven ability to address unmet medical needs with pioneering patient-centered approaches to accelerate the discovery of breakthrough therapies.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
“CELLnTEC is a pioneering provider of animal and human component-free, chemically defined precision media and technologies. Across the globe, CELLnTEC empowers scientists to conduct cell culture and tissue engineering, and to create sophisticated in vitro cell models in applications ranging from 2D/3D cell culture to organoids, lab-on-a-chip, or 3D bioprinting, across a range of tissue types, iPSC and ESC.
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to provide high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.
“As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders.
For more than 140 years, Elsevier has supported the work of our research and health partners. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research, and healthcare in developing countries and around the world.
Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Visit us at www.elsevier.com.”
Genemarkers is the leader in applying cutting-edge genomic technologies to the product development process. They have designed proprietary gene expression panels which screen for many functions such as anti-aging, acne, pigmentation, mitochondrial function & more. They can also challenge products with various stressors such as blue light or UV to determine any protective or reparative effects of products. Genemarkers is now offering next-generation sequencing, an innovative technology which detects novel and rare biomarkers, determines the effect of products on the skin/hair microbiome, and identifies epigenetic modification of aging, inflammation, and skin repair makers. Visit Genemarkers at Booth #109 or come visit us at Poster #621 during Poster Session 1 at to learn more about Genemarkers’ validated method for assessing the effects of blue light on the human skin. To schedule a time to meet, contact Alisha Morrison at email@example.com.
“Genoskin is a Partner Research Organization with unique expertise in skin biology and immunology. Our mission is to help pharmaceutical and biotechnology companies obtain reliable human data prior to clinical trials for drugs, vaccines, medical devices as well as cosmetics. We combine our live human data generation platforms with hi-tech tools, unbiased data analysis and expert advice to generate accurate data and help drug development projects move forward.
Genoskin provides a unique range of human skin platforms for reliable first-in-human testing purposes. As opposed to animal skin or engineered models, all our models only contain real human skin that is kept alive for 7 days after surgery, thanks to our proprietary technology. This approach allows for a full week of testing opportunities on all the types of cells and appendages of real, live human skin. Our ex vivo human skin models are immunocompetent and allow for subcutaneous or intradermal injection as well as systemic and topical route of administration.”
ImaBiotech’s mission is to measure all the parameters that will explain the drug efficacy and reveal the high potential of new medicines using the latest technologies and scientific expertise. In order to measure the parameters, we develop robust methods to quantify the exact amount of drug in contact to targeted cells in human and animal models. We are able to measure the impact of the new drugs with no doubt. Our mission is to accelerate the development of drugs with personalized approach for each customer.
Innovaderm Research Inc. is a global full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotech companies for the collaborative management of early to late phase clinical trials. A leader in the field, it offers a broad range of services including clinical trial management, patient recruitment, site selection, clinical monitoring, data management, biostatistics, medical monitoring, pharmacovigilance, regulatory and ethics submissions, protocol development, medical writing and study design. Pairing expertise with innovation, Innovaderm is internationally renowned for pioneering studies in different dermatology indications. Its mission is to drive research forward and offer new therapies for patients living with skin disease. For more information, please visit: http://www.innovaderm.com
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.
“iThera Medical develops and markets optoacoustic imaging (OAI) systems for preclinical and clinical research. OAI utilizes the photoacoustic effect to visualize and quantify optical contrast at several millimeters to centimeters depth, at high spatiotemporal resolution. In the context of dermatology, OAI has shown the potential to visualize and quantify changes in vascular morphology as well as skin perfusion and oxygenation associated with inflammatory skin diseases and skin cancer.”
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas.
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we apply cutting-edge science and expertise in antibody research and engineering to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four global regions – Japan, Asia Pacific, North America and EMEA/International – we are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity, and a drive to advance innovations that have a profound impact on patients. You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com.
Ten Bio provides optimal human skin models for skin biology testing. By restoring and maintaining physiological skin tension using our unique culture platform, Ten Bio has succeeded in creating a truly functional and realistic testing platform for skin-based research. Our products and research services help generate exacting and clinically relevant data to more accurately predict product performance in vivo. Ten Bio can significantly lower R&D costs and accelerate product development.
TissueVision Inc. is a multi-disciplinary life sciences company offering 3D tissue imaging and analysis solutions for the research market. Our powerful Serial Two-Photon Plus (STP²) platform features stunning high-resolution multispectral datasets and analysis pipelines that create informative 3D tissue models. The indexed histological sections produced during the STP² process can be further investigated with secondary analyses that run the gamut from standard histological stains to advanced spatial genomics.
Zen-Bio is a leading global provider of advanced cell-based solutions and services to the life science, cosmetics, and personal care communities. The company, founded in 1995, was a pioneer in adipose derived stem cells (ASCs) and continues this legacy by providing cutting edge human primary cell culture products and services. Our mission is to provide the highest quality human cell systems, reagents, blood products and contract services to our research partners; to develop and commercialize innovative research tools; and to leverage our expertise through research and development and strategic alliances that accelerate discovery.